A marriage made to last in drug design.
A marriage made to last in drug design.
复制标题
药物设计中的持久婚姻。
DOI：
10.1038/nm.3018
复制
发表时间：
2012
期刊：
影响因子：
82.9
通讯作者：
Horvath,TamasL
中科院分区：
文献类型：
--
作者：
Dietrich,MarceloO;Horvath,TamasL
许多机制可以导致复杂的疾病，如代谢性疾病;因此，可能需要联合治疗来靶向个体潜在的病理机制。一项新的研究将胰高血糖素样肽-1（GLP 1）和雌激素结合在一个分子中，允许这种缀合物选择性靶向表达GLP 1受体的细胞。这种策略改善了肥胖小鼠的代谢特征，而没有与雌激素治疗相关的不良副作用（第1847-1856页）。
Many mechanisms can contribute to complex diseases such as metabolic diseases; thus, combination therapies may be required to target individual underlying pathological mechanisms. A new study combines glucagon-like peptide-1 (GLP1) and estrogen in a single molecule, allowing selective targeting of this conjugate to cells that express the GLP1 receptor. This strategy improves the metabolic profile of obese mice without the adverse side effects associated with estrogen therapy (pages 1847–1856).